Vimarsana
Biggest News Aggregation in the World

Page 13 - Randomized Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Clinical Today - Breaking & Trending Today

Oral Muvalaplin effectively lowers lipoprotein (a) with no serious adverse effects, shows Initial phase 1 trial - Vimarsana News

Oral Muvalaplin effectively lowers lipoprotein (a) with no serious adverse effects, shows Initial phase 1 trial

Australia: Daily administration of Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, for 14 days lowered Lipoprotein(a) levels up to 65% and was not associated with tolerability...

Eating a vegan diet could reduce grocery bill - Vimarsana News

Eating a vegan diet could reduce grocery bill

Food costs decrease 16% on a low-fat vegan diet, a savings of more than $500 a year, compared to a diet that includes meat, dairy, and other animal products, according to a new analysis from the Physicians Committee for Responsible Medicine published in JAMA Network Open.

Portion Control For Weight Loss: How To Measure It 2023 - Vimarsana News

Portion Control For Weight Loss: How To Measure It 2023

Find out how to hit your diet goals with our tips on how to use portion control for weight loss! Here’s what you need to know in 2023.

Single-Dose Psilocybin Significantly Improves Major Depressive Disorder Symptoms Within 8 Days - Vimarsana News

Single-Dose Psilocybin Significantly Improves Major Depressive Disorder Symptoms Within 8 Days

New phase 2 data adds to the growing interest in the psychedelic treatment as a novel drug to treat MDD.

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans? - Vimarsana News

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.